Genky DrugStores Co., Ltd.
Notice Regarding Revision of Earnings Guidance
Operating income for the second quarter of the fiscal year ending June 2026 has been revised upward from 5,270 million yen to 5,717 million yen, an increase of 8.5%. Full-year operating income has also been revised upward from 10,500 million yen to 11,050 million yen, a 5.2% increase.
Key Figures
- 2nd Quarter Net Sales: 109,261 million yen (Compared to previous forecast +0.0%)
- 2nd Quarter Operating Income: 5,717 million yen (Compared to previous forecast +8.5%)
- Full Year Net Income Attributable to Owners of Parent: 7,850 million yen (Compared to previous forecast +4.7%)
AI要約
Summary of Earnings Guidance Revision
The consolidated earnings guidance for the second quarter and full fiscal year ending June 2026 has been revised. For the second quarter, net sales are nearly on plan, with expected increases of approximately 8% in operating income, ordinary income, and net income attributable to owners of parent. For the full year, net sales have been slightly lowered, but operating income and net income are forecasted to increase by around 5%. Cost control on labor and improvement in gross profit margin contributed in the first half.
Revision of Second Half Plan and Future Outlook
The number of store openings in the second half has been reduced from 45 to 41, decreasing the net sales plan by approximately 690 million yen. The main causes are rising construction costs and tight construction schedules. The number of store closures remains as planned at 3 stores, expecting a net increase of 58 stores for the full year. The company continues to aim for 100 store openings annually and will strengthen the store development division. While increased interest expenses impact ordinary income, efforts to improve rental income are also underway.
